Stockreport

CorMedix: The Post-TDAPA Hangover Arrived Early (Rating Downgrade) [Seeking Alpha]

CorMedix Inc.  (CRMD) 
NASDAQ:AMEX Investor Relations: cormedix.com
PDF CRMD's 2026 revenue guidance of $300-$320 million materially misses consensus, reflecting DefenCath's post-TDAPA pressures and a challenging outlook. Pipeline focus s [Read more]